Aerosolized Anti-Human CD3 Antibodies Decrease Airway Hyperresponsiveness in Non-Human Primates
National Jewish Health
*Method proven in mice
Researchers at National Jewish Health have discovered that the targeted delivery of anti alpha/beta or gamma/delta T cell monoclonal antibodies can be used as a means to manipulate T cell-dependent regulation of airway reactivity. They have demonstrated that the use of such antibodies can significantly decrease airway hyperreactivity (AHR) in a mouse model of asthma. Therefore, the use of monoclonal antibodies anti-alpha beta or gamma delta T cells could constitute a treatment for asthma and other allergic diseases of the airways.
Therapy for asthma and chronic obstructive pulmonary disease
Advantages of Invention
- Monoclonal antibodies are specific and therefore various subsets of T cell population can be targeted.
- Low doses of antibody are required.
- The therapeutical effects of such technique are rapid.
- The delivery of these antibodies is confined to the airways and does not affect the peripheral immune system.
State of Development
National Jewish Health scientists have demonstrated in a mouse model of asthma that targeted delivery of monoclonal antibodies anti-alpha beta or gamma delta T cells alleviate AHR:
In addition, the same decrease inAHR was demonstrated in mice genetically-deficient in cells targeted by these antibodies. The same scientists have also shown that the cellular effects of these antibodies is localized exclusively to the airways and do not spread systemically .
Further R&D Required
Applying this technology to other model systems.
This technology is available for licensing.
U.S. Patent #8,178,098.
- Willi Born, PhD, Erwin W. Gelfand, MD, Michael Lahn, MD and Arihiko Kanehiro, MD Publications Lahn et al. Int Arch Allergy Immunol. 2004; 134 (1):49-55
- Lahn et al. Proc. Natl. Acad. Sci. USA, June 25, 2002, 99(13):8850-8855